Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania
<p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to s...
Ausführliche Beschreibung
Autor*in: |
Berens-Riha Nicole [verfasserIn] Maboko Leonard [verfasserIn] Hoelscher Michael [verfasserIn] Maduhu Ibrahim [verfasserIn] Schunk Mirjam [verfasserIn] Barreto Miranda Isabel [verfasserIn] Schönfeld Mirjam [verfasserIn] Kitua Andrew [verfasserIn] Löscher Thomas [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2007 |
---|
Übergeordnetes Werk: |
In: Malaria Journal - BMC, 2003, 6(2007), 1, p 2 |
---|---|
Übergeordnetes Werk: |
volume:6 ; year:2007 ; number:1, p 2 |
Links: |
---|
DOI / URN: |
10.1186/1475-2875-6-2 |
---|
Katalog-ID: |
DOAJ037123122 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ037123122 | ||
003 | DE-627 | ||
005 | 20230308000407.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2007 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/1475-2875-6-2 |2 doi | |
035 | |a (DE-627)DOAJ037123122 | ||
035 | |a (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC955-962 | |
050 | 0 | |a RC109-216 | |
100 | 0 | |a Berens-Riha Nicole |e verfasserin |4 aut | |
245 | 1 | 0 | |a Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania |
264 | 1 | |c 2007 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a <p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< | ||
653 | 0 | |a Arctic medicine. Tropical medicine | |
653 | 0 | |a Infectious and parasitic diseases | |
700 | 0 | |a Maboko Leonard |e verfasserin |4 aut | |
700 | 0 | |a Hoelscher Michael |e verfasserin |4 aut | |
700 | 0 | |a Maduhu Ibrahim |e verfasserin |4 aut | |
700 | 0 | |a Schunk Mirjam |e verfasserin |4 aut | |
700 | 0 | |a Barreto Miranda Isabel |e verfasserin |4 aut | |
700 | 0 | |a Schönfeld Mirjam |e verfasserin |4 aut | |
700 | 0 | |a Kitua Andrew |e verfasserin |4 aut | |
700 | 0 | |a Löscher Thomas |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Malaria Journal |d BMC, 2003 |g 6(2007), 1, p 2 |w (DE-627)355986582 |w (DE-600)2091229-8 |x 14752875 |7 nnns |
773 | 1 | 8 | |g volume:6 |g year:2007 |g number:1, p 2 |
856 | 4 | 0 | |u https://doi.org/10.1186/1475-2875-6-2 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 |z kostenfrei |
856 | 4 | 0 | |u http://www.malariajournal.com/content/6/1/2 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1475-2875 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 6 |j 2007 |e 1, p 2 |
author_variant |
b r n brn m l ml h m hm m i mi s m sm b m i bmi s m sm k a ka l t lt |
---|---|
matchkey_str |
article:14752875:2007----::oeuasrelacodurssacascaemttosftlsoimac |
hierarchy_sort_str |
2007 |
callnumber-subject-code |
RC |
publishDate |
2007 |
allfields |
10.1186/1475-2875-6-2 doi (DE-627)DOAJ037123122 (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7 DE-627 ger DE-627 rakwb eng RC955-962 RC109-216 Berens-Riha Nicole verfasserin aut Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< Arctic medicine. Tropical medicine Infectious and parasitic diseases Maboko Leonard verfasserin aut Hoelscher Michael verfasserin aut Maduhu Ibrahim verfasserin aut Schunk Mirjam verfasserin aut Barreto Miranda Isabel verfasserin aut Schönfeld Mirjam verfasserin aut Kitua Andrew verfasserin aut Löscher Thomas verfasserin aut In Malaria Journal BMC, 2003 6(2007), 1, p 2 (DE-627)355986582 (DE-600)2091229-8 14752875 nnns volume:6 year:2007 number:1, p 2 https://doi.org/10.1186/1475-2875-6-2 kostenfrei https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 kostenfrei http://www.malariajournal.com/content/6/1/2 kostenfrei https://doaj.org/toc/1475-2875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2007 1, p 2 |
spelling |
10.1186/1475-2875-6-2 doi (DE-627)DOAJ037123122 (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7 DE-627 ger DE-627 rakwb eng RC955-962 RC109-216 Berens-Riha Nicole verfasserin aut Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< Arctic medicine. Tropical medicine Infectious and parasitic diseases Maboko Leonard verfasserin aut Hoelscher Michael verfasserin aut Maduhu Ibrahim verfasserin aut Schunk Mirjam verfasserin aut Barreto Miranda Isabel verfasserin aut Schönfeld Mirjam verfasserin aut Kitua Andrew verfasserin aut Löscher Thomas verfasserin aut In Malaria Journal BMC, 2003 6(2007), 1, p 2 (DE-627)355986582 (DE-600)2091229-8 14752875 nnns volume:6 year:2007 number:1, p 2 https://doi.org/10.1186/1475-2875-6-2 kostenfrei https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 kostenfrei http://www.malariajournal.com/content/6/1/2 kostenfrei https://doaj.org/toc/1475-2875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2007 1, p 2 |
allfields_unstemmed |
10.1186/1475-2875-6-2 doi (DE-627)DOAJ037123122 (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7 DE-627 ger DE-627 rakwb eng RC955-962 RC109-216 Berens-Riha Nicole verfasserin aut Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< Arctic medicine. Tropical medicine Infectious and parasitic diseases Maboko Leonard verfasserin aut Hoelscher Michael verfasserin aut Maduhu Ibrahim verfasserin aut Schunk Mirjam verfasserin aut Barreto Miranda Isabel verfasserin aut Schönfeld Mirjam verfasserin aut Kitua Andrew verfasserin aut Löscher Thomas verfasserin aut In Malaria Journal BMC, 2003 6(2007), 1, p 2 (DE-627)355986582 (DE-600)2091229-8 14752875 nnns volume:6 year:2007 number:1, p 2 https://doi.org/10.1186/1475-2875-6-2 kostenfrei https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 kostenfrei http://www.malariajournal.com/content/6/1/2 kostenfrei https://doaj.org/toc/1475-2875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2007 1, p 2 |
allfieldsGer |
10.1186/1475-2875-6-2 doi (DE-627)DOAJ037123122 (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7 DE-627 ger DE-627 rakwb eng RC955-962 RC109-216 Berens-Riha Nicole verfasserin aut Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< Arctic medicine. Tropical medicine Infectious and parasitic diseases Maboko Leonard verfasserin aut Hoelscher Michael verfasserin aut Maduhu Ibrahim verfasserin aut Schunk Mirjam verfasserin aut Barreto Miranda Isabel verfasserin aut Schönfeld Mirjam verfasserin aut Kitua Andrew verfasserin aut Löscher Thomas verfasserin aut In Malaria Journal BMC, 2003 6(2007), 1, p 2 (DE-627)355986582 (DE-600)2091229-8 14752875 nnns volume:6 year:2007 number:1, p 2 https://doi.org/10.1186/1475-2875-6-2 kostenfrei https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 kostenfrei http://www.malariajournal.com/content/6/1/2 kostenfrei https://doaj.org/toc/1475-2875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2007 1, p 2 |
allfieldsSound |
10.1186/1475-2875-6-2 doi (DE-627)DOAJ037123122 (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7 DE-627 ger DE-627 rakwb eng RC955-962 RC109-216 Berens-Riha Nicole verfasserin aut Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< Arctic medicine. Tropical medicine Infectious and parasitic diseases Maboko Leonard verfasserin aut Hoelscher Michael verfasserin aut Maduhu Ibrahim verfasserin aut Schunk Mirjam verfasserin aut Barreto Miranda Isabel verfasserin aut Schönfeld Mirjam verfasserin aut Kitua Andrew verfasserin aut Löscher Thomas verfasserin aut In Malaria Journal BMC, 2003 6(2007), 1, p 2 (DE-627)355986582 (DE-600)2091229-8 14752875 nnns volume:6 year:2007 number:1, p 2 https://doi.org/10.1186/1475-2875-6-2 kostenfrei https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 kostenfrei http://www.malariajournal.com/content/6/1/2 kostenfrei https://doaj.org/toc/1475-2875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2007 1, p 2 |
language |
English |
source |
In Malaria Journal 6(2007), 1, p 2 volume:6 year:2007 number:1, p 2 |
sourceStr |
In Malaria Journal 6(2007), 1, p 2 volume:6 year:2007 number:1, p 2 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Arctic medicine. Tropical medicine Infectious and parasitic diseases |
isfreeaccess_bool |
true |
container_title |
Malaria Journal |
authorswithroles_txt_mv |
Berens-Riha Nicole @@aut@@ Maboko Leonard @@aut@@ Hoelscher Michael @@aut@@ Maduhu Ibrahim @@aut@@ Schunk Mirjam @@aut@@ Barreto Miranda Isabel @@aut@@ Schönfeld Mirjam @@aut@@ Kitua Andrew @@aut@@ Löscher Thomas @@aut@@ |
publishDateDaySort_date |
2007-01-01T00:00:00Z |
hierarchy_top_id |
355986582 |
id |
DOAJ037123122 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ037123122</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308000407.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2007 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1475-2875-6-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ037123122</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC955-962</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC109-216</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Berens-Riha Nicole</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Arctic medicine. Tropical medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Infectious and parasitic diseases</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maboko Leonard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hoelscher Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maduhu Ibrahim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schunk Mirjam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Barreto Miranda Isabel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schönfeld Mirjam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kitua Andrew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Löscher Thomas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Malaria Journal</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">6(2007), 1, p 2</subfield><subfield code="w">(DE-627)355986582</subfield><subfield code="w">(DE-600)2091229-8</subfield><subfield code="x">14752875</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:1, p 2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1475-2875-6-2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.malariajournal.com/content/6/1/2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1475-2875</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2007</subfield><subfield code="e">1, p 2</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Berens-Riha Nicole |
spellingShingle |
Berens-Riha Nicole misc RC955-962 misc RC109-216 misc Arctic medicine. Tropical medicine misc Infectious and parasitic diseases Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania |
authorStr |
Berens-Riha Nicole |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)355986582 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC955-962 |
illustrated |
Not Illustrated |
issn |
14752875 |
topic_title |
RC955-962 RC109-216 Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania |
topic |
misc RC955-962 misc RC109-216 misc Arctic medicine. Tropical medicine misc Infectious and parasitic diseases |
topic_unstemmed |
misc RC955-962 misc RC109-216 misc Arctic medicine. Tropical medicine misc Infectious and parasitic diseases |
topic_browse |
misc RC955-962 misc RC109-216 misc Arctic medicine. Tropical medicine misc Infectious and parasitic diseases |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Malaria Journal |
hierarchy_parent_id |
355986582 |
hierarchy_top_title |
Malaria Journal |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)355986582 (DE-600)2091229-8 |
title |
Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania |
ctrlnum |
(DE-627)DOAJ037123122 (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7 |
title_full |
Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania |
author_sort |
Berens-Riha Nicole |
journal |
Malaria Journal |
journalStr |
Malaria Journal |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2007 |
contenttype_str_mv |
txt |
author_browse |
Berens-Riha Nicole Maboko Leonard Hoelscher Michael Maduhu Ibrahim Schunk Mirjam Barreto Miranda Isabel Schönfeld Mirjam Kitua Andrew Löscher Thomas |
container_volume |
6 |
class |
RC955-962 RC109-216 |
format_se |
Elektronische Aufsätze |
author-letter |
Berens-Riha Nicole |
doi_str_mv |
10.1186/1475-2875-6-2 |
author2-role |
verfasserin |
title_sort |
molecular surveillance of drug-resistance associated mutations of <it<plasmodium falciparum </it<in south-west tanzania |
callnumber |
RC955-962 |
title_auth |
Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania |
abstract |
<p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< |
abstractGer |
<p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< |
abstract_unstemmed |
<p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
1, p 2 |
title_short |
Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania |
url |
https://doi.org/10.1186/1475-2875-6-2 https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 http://www.malariajournal.com/content/6/1/2 https://doaj.org/toc/1475-2875 |
remote_bool |
true |
author2 |
Maboko Leonard Hoelscher Michael Maduhu Ibrahim Schunk Mirjam Barreto Miranda Isabel Schönfeld Mirjam Kitua Andrew Löscher Thomas |
author2Str |
Maboko Leonard Hoelscher Michael Maduhu Ibrahim Schunk Mirjam Barreto Miranda Isabel Schönfeld Mirjam Kitua Andrew Löscher Thomas |
ppnlink |
355986582 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1186/1475-2875-6-2 |
callnumber-a |
RC955-962 |
up_date |
2024-07-04T00:00:48.438Z |
_version_ |
1803604457899950080 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ037123122</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308000407.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2007 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1475-2875-6-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ037123122</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC955-962</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC109-216</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Berens-Riha Nicole</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Arctic medicine. Tropical medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Infectious and parasitic diseases</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maboko Leonard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hoelscher Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maduhu Ibrahim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schunk Mirjam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Barreto Miranda Isabel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schönfeld Mirjam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kitua Andrew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Löscher Thomas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Malaria Journal</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">6(2007), 1, p 2</subfield><subfield code="w">(DE-627)355986582</subfield><subfield code="w">(DE-600)2091229-8</subfield><subfield code="x">14752875</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:1, p 2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1475-2875-6-2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.malariajournal.com/content/6/1/2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1475-2875</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2007</subfield><subfield code="e">1, p 2</subfield></datafield></record></collection>
|
score |
7.4004774 |